The shares of the Small-cap company, specializing in integrated biorefinery operations, specifically focusing on bio-based chemicals, ethanol, and sugar production, hit a 5 percent upper circuit upon receiving a Chinese patent for an Anti-Cancer Molecule, which has shown strong lab results against breast and prostate cancer.
With a market capitalization of Rs. 1,672.43 Crores on Tuesday, the shares of Godavari Biorefineries Ltd hit a 5 percent upper circuit after making a high of Rs. 326.80 compared to its previous closing price of Rs. 311.25.
Godavari Biorefineries Ltd, through its biotech division Sathgen Therapeutics, has been granted a Chinese patent for its breakthrough anti-cancer molecule, HYDROXY-1,4-NAPHTHALENEDIONE.
This novel compound has shown strong lab results in inhibiting cancer and cancer stem cells, particularly in breast and prostate cancers. The patent, issued by China’s national patent office (CNIPA), strengthens the company’s intellectual property portfolio and global research footprint.
Executive Director, Godavari Biorefineries Limited, Dr. Sangeeta Srivastava, emphasized that this achievement reflects the company’s commitment to high-quality science and innovation beyond its traditional green chemistry roots.
With exports to over 20 countries and a lead molecule currently in clinical trials, Godavari Biorefineries is expanding its focus into life sciences, aiming to develop impactful cancer and antiviral therapies that address critical global health needs.
Financials & Others
The company’s revenue declined by 5.9 percent from Rs. 625.74 crore to Rs. 588.75 crore in Q4FY24-25. Meanwhile, the Net profit rose from Rs. 65.17 crore to Rs. 71.93 crore during the same period.
In Q4 FY25, Godavari Biorefineries’ revenue came mainly from three segments: Distillery contributed the highest at 42%, followed by Sugar & Co-Generation at 33%, and Bio-based Chemicals at 24%.
Godavari Biorefineries Ltd. (GBL) is a leading Indian manufacturer of ethanol-based chemicals and a major player in the bio-refining industry. It is the company in India to have such a vast portfolio of bio-based products and is also the largest manufacturer of MPO worldwide, one of only two manufacturers of natural 1,3 butylene glycol globally, the fourth largest manufacturer of ethyl acetate in India, and the only company in India to produce bio-ethyl acetate.
They operate an integrated bio-refinery, producing a diverse range of products including bio-based chemicals, sugar, various grades of ethanol, and power, utilizing sugarcane as their primary feedstock.
Written by Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
